Furthermore, KRAS non-synonymous mutations G15S and V7A appearing in concordance in our study were also detected to co-occur in gastric cancer patients who had been identified with therapeutic resistance, suggesting the importance of a new evaluation of the KRAS mutation and co-occurrence of other mutations’ effect in other cancers as well as lung cancer [48]. This evidence concerns the gene KRAS and gastric cancer.